{"id":"teta-4hcl-formulation","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Hypokalemia"},{"rate":"5-10%","effect":"QT interval prolongation"},{"rate":"null","effect":"Arrhythmias"}]},"_chembl":{"chemblId":"CHEMBL287258","moleculeType":"Small molecule","molecularWeight":"508.41"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TETA 4HCl formulation works by blocking potassium channels, which can help to stabilize cardiac membranes and prevent arrhythmias. This mechanism is thought to be beneficial in the treatment of certain cardiac conditions.","oneSentence":"TETA 4HCl formulation is a tetraethylammonium chloride, a potassium channel blocker.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:09.435Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT07465718","phase":"PHASE3","title":"Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.","status":"NOT_YET_RECRUITING","sponsor":"Orphalan","startDate":"2026-05","conditions":"Wilson's Disease","enrollment":38},{"nctId":"NCT07010575","phase":"PHASE2","title":"Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride","status":"COMPLETED","sponsor":"Orphalan","startDate":"2025-07-15","conditions":"Wilson's Disease","enrollment":10},{"nctId":"NCT06128954","phase":"PHASE1","title":"Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).","status":"COMPLETED","sponsor":"Orphalan","startDate":"2024-01-16","conditions":"Wilson's Disease","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TETA 4HCl formulation","genericName":"TETA 4HCl formulation","companyName":"Orphalan","companyId":"orphalan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TETA 4HCl formulation is a tetraethylammonium chloride, a potassium channel blocker. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}